Allison Jonathan sold $260K of ROOT

Allison Jonathan (Chief Administrative Officer) sold 5,924 shares of Root, Inc. (ROOT) at an average of $43.81 ($43.59–$44.03, $0.26M total) across 2 trades over 2026-11-12 to 2026-11-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Allison Jonathan
Published Nov 16, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ROOT
Neutral
high confidence
Mentioned
$ROOT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROOTNeutralLow
01

Why it matters

Because the sale is under a pre-arranged Rule 10b5-1 plan, it generally carries less signaling value than discretionary selling, and it does not introduce new operating or financial information.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental catalyst to drive a durable repricing.

03

What to watch

The sale size is modest relative to typical institutional flows, and the trades occurred days before the filing, reducing any immediate informational edge.

Relevance 3/10Novelty 2/10Timing: filed after-hours on 2026-11-16; reflects trades dated 2026-11-12 to 2026-11-13

Background

The article is an SEC Form 4 insider transaction disclosure for Root, Inc., reporting an open-market sale by Chief Administrative Officer Allison Jonathan.

Company-level read

Ticker impact

$ROOTNeutralHigh confidence
Context

Root, Inc. insider Allison Jonathan sold about 5,924 shares for roughly $259.5K under a pre-arranged 10b5-1 plan, per SEC Form 4.

Expected impact

Likely limited near-term impact as the sale is explicitly under a pre-arranged 10b5-1 plan; any reaction would be more sentiment-driven than fundamentals-driven.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with stated 10b5-1 pre-arrangement, and it does not include new company fundamentals, guidance, or legal/operational developments.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None.

None.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a lack of conviction, especially if it coincides with other negative signals not mentioned here.

Key entities

  • Root, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Allison Jonathan

    Chief Administrative Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ROOTMed

Root (ROOT) Q3 2026 Earnings Call Transcript

Root (ROOT) reported Q3 2026 revenue of $381M (down from $388M YoY) and net income of $14M (vs. a $5M loss YoY). Policies in force grew 4% YoY to 484,000, while gross written premiums decreased 8%. Management highlighted pricing discipline, strategic partnerships, and geographic expansion to 38 states. They guided Q4 loss ratio to the high end of the 60-65% range due to seasonal factors.

$ROOTMed

Root Q3 Earnings Call Highlights

Root (NASDAQ:ROOT) expects policies in force at year-end to align with Q3 levels, with $5M invested in marketing and R&D. Q4 loss ratio may rise due to seasonal factors. The company repurchased $36M in shares and developed a new pricing algorithm, aiming for higher conversion rates and potential premium declines. Growth drivers for 2027 include state expansion and partnerships, though competition remains uncertain.

$ROOTMed

Root Inc (ROOT) Q3 2026 Earnings Call Highlights: Profitability Surges With $14 Million

Root Inc (ROOT) reported Q3 2026 net income of $14M, up from a $5M loss last year, with revenue at $381M. CEO Alexander Timm highlighted growth strategies, including state expansions, AI-driven pricing, and partnerships. The company aims for national reach by late 2027, with continued investment in technology and channels. ROE was 18% this quarter, 25% over the last 12 months. Policies in force rose 4% year-over-year to 484,000.

$ROOTMed

Root, Inc. (ROOT): Letter to Shareholders: Q3 2026

Root, Inc. (ROOT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Letter to Shareholders: Q3 2026 ____________________________________________________________________________________________________________ Key quarterly metrics Dear Root Shareholders In the third quarter, Root delivered another quarter of strong profitability while continuing

$ROOTMed

Root (ROOT) Q2 2026 Earnings Call Transcript

Root (ROOT) held its Q2 2026 earnings call, saying it is building an AI-driven insurance platform. Management cited 2% YoY revenue growth to $389M, gross written premium down 2% to $340M, policies in force up 6% to 484,000, and a 92.1% net combined ratio. It also reported a $200M debt facility refinance, $20M+ share repurchases, and plans to launch a new predictive pricing model later this year.

$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.